Under the settlement, Medacta will receive a non-exclusive license to some Conformis patents related to patient-specific instruments with knee and shoulder implants, Conformis said Nov. 14. Medacta on Nov. 15 said the settlement also “contemplates the payment of a sum in a low single digit million-dollar amount.”
“Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our patient-specific implant products and services,” Conformis President and CEO Mark Augusti said in a statement.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
